5 assets in Bladder Urachal Adenocarcinoma

Therapeutic assets addressing Bladder Urachal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Bladder Urachal Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Bladder Urachal Adenocarcinoma	Emory University	P2	CCC (53)
Ipilimumab Bladder Urachal Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Bladder Urachal Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Bladder Urachal Adenocarcinoma	Emory University	P2	CCC (53)